Search filters

List of works by Jedd D. Wolchok

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

scientific article (publication date: November 2016)

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

scientific article published oln 16 November 2016

A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling

scientific article published on 26 August 2016

A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma

scientific article published on 23 March 2020

A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.

scientific article published on 8 November 2017

A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma

scientific article published on 12 June 2014

A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma

scientific article published on 19 January 2016

A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen

scientific article published in May 2003

Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab

scientific article published on 01 February 2020

Abstract 2402: GITR cancer immunotherapy: Epitope swapping of anti-GITR TRX518 to inform functional translatability from mouse to human

scholarly article

Abstract 2711: Rational combination of GITR agonism with PD-1 blockade

scholarly article

Abstract 3735: An anti-tumor immune response is evoked by partial-volume single dose radiation

scholarly article

Abstract 4041: Coupling neoantigen specific T cell clonotypes and their molecular phenotypes at the single cell level in resectable anti-PD-1 treated NSCLC

scholarly article

Abstract 4843: TP53-stabilization with APR-246 enhances antitumor effects of immune checkpoint blockade in preclinical models

scholarly article

Abstract 978: Tim-4+ tissue-resident macrophages impair antitumor T-cell immunity

scholarly article

Abstract CT037: Genomic analyses and immunotherapy in advanced melanoma

scholarly article

Abstract CT104: Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome

article

Abstract LB-081: A nuclear cAMP microdomain functions as a tumor suppressor in melanoma

scholarly article

Acquired resistance to immunotherapy in MMR-D pancreatic cancer

scientific article published on 20 November 2018

Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c+CD103+ Monocytic Antigen-Presenting Cells in Tumors

scientific article published in January 2018

Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy

scientific article published on 18 December 2018

Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins

scientific article published on 14 June 2018

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

scientific article published on 31 March 2015

Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial

scientific article published on 07 August 2019

Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains

scientific article

Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology

scientific article published on 21 March 2019

Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells

scientific article published on March 1, 2013

Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity

scientific article

Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation

scientific article

Alan Houghton

scientific article published on March 27, 2012

Alphavirus Replicon Particles Expressing TRP-2 Provide Potent Therapeutic Effect on Melanoma through Activation of Humoral and Cellular Immunity

scientific article (publication date: 10 September 2010)

Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers

scientific article published on 28 February 2018

Altered development of NKT cells, γδ T cells, CD8 T cells and NK cells in a PLZF deficient patient

scientific article

Altered self: the not-so-neo-antigens

scientific article published on 5 February 2018

An Anti-Tumor Immune Response is Evoked By Partial-Volume Single Dose Radiation in Two Murine Models

scientific article published on 18 October 2018

An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity

scientific article published in January 2016

An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma

scientific article published on 19 October 2016

Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade

scientific article published on 01 April 2019

Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice

scientific article published on 20 February 2014

Anatomic position determines oncogenic specificity in melanoma

scientific article published in April 2022

Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy

scientific article published on October 2010

Anti-GITR antibodies--potential clinical applications for tumor immunotherapy

scientific article published on December 1, 2010

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

scientific article (publication date: 20 September 2014)

Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine

scientific article

Antibody therapy of cancer

scientific article

Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

scientific article

Antigens recognized by autologous antibodies of patients with soft tissue sarcoma

scientific article

Antitumour immunity gets a boost

scientific article published in Nature

Artificial Antigen Presenting Cells Expand NY-ESO-1 Antigen-Specific CD8+ T Cells From Patients with Melanoma

scholarly article

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

scientific article published on April 2016

At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy

scientific article published on May 10, 2013

Author Correction: Fundamental immune–oncogenicity trade-offs define driver mutation fitness

correction of a scholarly article

Author Correction: PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance

scientific article published on 01 November 2019

Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.

scientific article published on 29 February 2016

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

scientific article

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

scientific article published on 19 January 2016

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

article

Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy

scientific article

Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types

scientific article published on March 1, 2013

Blockade of Treg derived TGF-β abrogates suppression of effector T cell function within the tumor microenvironment

scientific article published on 7 November 2013

Blockade of surface bound TGF-β abrogates Treg suppression of effector T cell function within the tumor microenvironment.

scientific article published on 6 November 2014

Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment

scientific article

Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine

scientific article published on 11 August 2020

CCR 20th Anniversary Commentary: Immune-Related Response Criteria--Capturing Clinical Activity in Immuno-Oncology.

scientific article

CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors

scientific article published on 17 February 2020

CD4 help and tumor immunity: beyond the activation of cytotoxic T lymphocytes

scientific article published on 20 September 2004

CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma.

scientific article published in January 2005

CMET-11. LEPTOMENINGEAL MELANOMA METASTASIS PRESENTING AS INTRAVENTRICULAR AND SUBARACHNOID HEMORRHAGE

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic

scientific article

CTLA-4 antibodies: new directions, new combinations.

scientific article

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit

scholarly article

CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems

scientific article published on April 2004

CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases

scientific article published on 5 April 2011

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

scientific article (publication date: 3 April 2015)

Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies

scientific article published on 20 January 2017

Cancer immunotherapy using checkpoint blockade.

scientific article published on 22 March 2018

Cancer's off switch

scientific article published on 01 May 2014

Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade

scientific article published on 6 April 2018

Characterization of computed tomography scan abnormalities in patients with biopsy-proven hepatic metastases from uveal melanoma

scientific article published in December 2011

Checkpoint Blockade in Melanoma Patients With Underlying Chronic Lymphocytic Leukemia

scientific article published on 01 January 2021

Checkpoint Modulation in Melanoma: An Update on Ipilimumab and Future Directions

scientific article published on October 1, 2013

Checkpoint inhibition and melanoma: Considerations in treating the older adult

scientific article published on 11 May 2017

Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma.

scientific article

Chromatin states define tumour-specific T cell dysfunction and reprogramming.

scientific article

Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling

scientific article published in May 2003

Classification of current anticancer immunotherapies

scientific article

Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review

scientific article

Clinical Activity, Toxicity, Biomarkers, and Future Development of CTLA-4 Checkpoint Antagonists

scientific article published on 03 June 2015

Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience

scientific article published on 02 August 2013

Clinical benefit and toxicity of nivolumab plus ipilimumab in patients with advanced melanoma previously treated with checkpoint blockade inhibitors.

scholarly article

Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma

scientific article published on 27 October 2016

Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors

scientific article published on 7 June 2016

Clonal Abundance of Tumor-Specific CD4(+) T Cells Potentiates Efficacy and Alters Susceptibility to Exhaustion

scientific article published on January 2016

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

scientific article published on 03 March 2016

Combination immunotherapy: a road map.

scientific article

Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates.

scientific article published on 26 February 2014

Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice

scientific article published on March 22, 2011

Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo

scientific article

Combinatorial Cancer Immunotherapies

scientific article published on 12 January 2016

Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient

scientific article published on 30 May 2016

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

scientific article (publication date: 2 July 2015)

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

scientific article published on 01 September 2015

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

scientific article

Combining cancer immunotherapy and targeted therapy

scientific article published on 02 April 2013

Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles

scientific article published on November 2005

Completely regressed cutaneous melanocytic lesion: was it benign or was it malignant?

scientific article published on 01 October 2009

Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes

scientific article

Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma

scientific article published on 25 July 2013

Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

scientific article published on 08 September 2020

Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

scientific article published on 05 December 2020

Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21

scientific article published on 01 November 2003

Correction to: Strategies for Predicting Response to Checkpoint Inhibitors

scientific article published on 01 February 2019

Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

scientific article published on 01 December 2018

Correction: Frequent MAGE Mutations in Human Melanoma.

scientific article

Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy

scientific article

Corrigendum: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET

scientific article published on 01 December 2016

Curbing Tregs' (Lack of) Enthusiasm

scientific article published on 01 June 2017

Current topics in melanoma

scientific article published on March 2007

Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy.

scientific article published on 27 January 2014

Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right

scientific article

Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs

scientific article

DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantation.

scientific article published on September 2006

DNA vaccines against cancer.

scientific article published on June 2006

DNA vaccines for melanoma

scientific article

DNA vaccines: an active immunization strategy for prostate cancer

scientific article published on October 2003

Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy

scientific article published on September 2016

Defining the critical hurdles in cancer immunotherapy

scientific article published on 14 December 2011

Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment

scientific article published on 08 April 2016

Depression, cytokines, and pancreatic cancer

scientific article

Detection of intra-tumor self antigen recognition during melanoma tumor progression in mice using advanced multimode confocal/two photon microscope

scientific article (publication date: 2011)

Determinants of COVID-19 disease severity in patients with cancer

scientific article published on 24 June 2020

Determinants of Severity in Cancer Patients with COVID-19 Illness

scientific article published on 08 May 2020

Development of effective vaccines for old mice in a tumor model

scientific article

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

scientific article published on 17 June 2013

Different Faces of Hepatotoxicity in Patients With Metastatic Melanoma on Combination Vemurafenib and Ipilimumab Therapy

scholarly article

Diffuse melanosis after chemotherapy-induced tumor lysis syndrome in a patient with metastatic melanoma

scientific article published in March 2004

Direct comparisons of T cell costimulation and checkpoint blockade in the setting of tumor-targeted monoclonal antibody therapy.

scientific article published on 4 November 2015

Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database

scientific article published on January 2009

Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease

scientific article published on 12 February 2014

Dual mode reflectance and fluorescence confocal laser scanning microscopy for in vivo imaging melanoma progression in murine skin

scientific article published in October 2005

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma

scientific article published on 28 December 2017

Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.

scientific article

Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial

scientific article published on 18 June 2014

Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials

scientific article published on 25 August 2017

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

scientific article published on 7 November 2016

Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials

scientific article

Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL)

article

Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies

article

Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies.

scientific article published in April 2018

Emerging therapies in melanoma

scientific article published on November 1, 2012

Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution

scientific article

Enhanced responses to tumor immunization following total body irradiation are time-dependent

scientific article

Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients

scientific article published on October 2013

Erratum: Correlationof clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy.

scientific article

Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

scientific article published in March 2015

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

scientific article published on 07 March 2016

Evidence generation and reproducibility in cell and gene therapy research: A call to action

scientific article published in 2021

Expanded access programmes: patient interests versus clinical trial integrity

scientific article published on 29 December 2014

Expression of indoleamine 2.3-dioxygenase by tumors induces local and systemic immunosuppressive effects in a murine melanoma model

F-18 FDG PET/CT for monitoring of ipilimumab therapy in patients with metastatic melanoma

scientific article published on 09 November 2018

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

scientific article

First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting

scientific article published on 04 October 2019

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab

scientific article published on 25 July 2019

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

scientific article published on 28 September 2019

Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial

scientific article published on 23 February 2015

Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation

scientific article published on 16 September 2017

Frequent MAGE Mutations in Human Melanoma

scientific article published on September 16, 2010

Fundamental immune-oncogenicity trade-offs define driver mutation fitness

scientific article published in June 2022

Future cancer research priorities in the USA: a Lancet Oncology Commission

scientific article published on 31 October 2017

GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability

scientific article

GM-CSF DNA induces specific patterns of cytokines and chemokines in the skin: implications for DNA vaccines

scientific article published on 01 January 2002

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

article

Genetic basis for clinical response to CTLA-4 blockade

article

Genetic basis for clinical response to CTLA-4 blockade in melanoma

scientific article (publication date: 4 December 2014)

Genetics and immunology: reinvigorated

scientific article published on 14 April 2015

Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring

scientific article published on 01 June 2020

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

scientific article published on 12 April 2018

Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma

scientific article published on 26 May 2015

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

scientific article

Health-related quality of life results from the phase III CheckMate 067 study.

scientific article published on 22 June 2017

Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial

scientific article published on 2 February 2017

Hepatotoxicity with combination of vemurafenib and ipilimumab

scientific article

Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient.

scientific article published on August 2017

Hiding the road signs that lead to tumor immunity

scientific article

How can we tell when cancer vaccines vaccinate?

scientific article published on 01 February 2003

ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity

scientific article published on 19 February 2020

IMMUNOTHERAPY. Could microbial therapy boost cancer immunotherapy?

scientific article published in November 2015

Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation

scientific article published on 29 April 2015

Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics

scientific article published on 01 February 2005

Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.

scientific article published on 8 November 2017

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.

scientific article published on 28 August 2011

Immigration in science

scientific article published on 01 November 2020

Immune checkpoint blockade

scientific article published on June 2014

Immune modulation in cancer with antibodies

scientific article published on 30 October 2013

Immune regulatory antibodies: are they the next advance?

scientific article published on July 2010

Immune rejection of mouse tumors expressing mutated self.

scientific article published on 7 April 2009

Immune-Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era

scientific article published on 15 June 2020

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy

scientific article published on 17 January 2018

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

scientific article published on 17 August 2015

Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy

scientific article

Immunity to cancer through immune recognition of altered self: studies with melanoma

scientific article

Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity

scientific article

Immuno-oncology safety education experience: Key lessons from ipilimumab (IPI).

scientific article published on 4 November 2015

Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials

scientific article

Immunologic correlates of the abscopal effect in a patient with melanoma

scientific article (publication date: 8 March 2012)

Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection.

scientific article

Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma

scientific article

Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma.

scientific article published on 17 May 2013

Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes

scientific article published on 4 June 2007

Immunomodulatory therapy for melanoma: Ipilimumab and beyond

scientific article published on March 1, 2013

Immunotherapy and the belly of the beast

scientific article

Immunotherapy of Melanoma

scientific article published on 4 September 2015

Immunotherapy of Melanoma: Facts and Hopes

scientific article published on 28 March 2019

Immunotherapy: The path to win the war on cancer?

scientific article published in April 2015

Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers

scientific article published on 12 May 2020

Impairment of Treg suppression by GITR ligation is effective selectively in the context of a pro-inflammatory tumor microenvironment.

scientific article published on 6 November 2014

Improved Endpoints for Cancer Immunotherapy Trials

scientific article published on September 8, 2010

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

scientific article (publication date: 19 August 2010)

Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma

scientific article published on December 2008

Improving the therapeutic benefits of ipilimumab

scientific article published on December 1, 2010

In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors

scientific article published on 22 July 2019

In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide

scientific article

Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy

scientific article published on 31 July 2013

Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab

scientific article

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4.

scientific article published on 7 November 2013

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.

scientific article published on 10 June 2013

Induction of autoantibodies against tyrosinase-related proteins following DNA vaccination: unexpected reactivity to a protein paralogue

scientific article published on July 19, 2002

Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination

scientific article

Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype

scientific article

Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child

scientific article published on 28 June 2021

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

scientific article

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

scientific article published on 25 February 2016

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

scientific article published on 01 April 2017

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

scientific article

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis

scientific article published on 2 February 2016

Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells

scientific article published on May 2017

Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity

scientific article published on 13 February 2017

Intravitreous Cutaneous Metastatic Melanoma in the Era of Checkpoint Inhibition: Unmasking and Masquerading

scientific article published on 24 September 2019

Introducing a New Series: Immunotherapy Facts and Hopes

scientific article published on 23 February 2018

Introduction by the Guest Editors: The PD-1 Axis in Cancer Therapy: The Irony in a Name

scientific article published on 01 January 2018

Ipilimumab and whole brain radiation therapy for melanoma brain metastases

scientific article published on 02 October 2014

Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials

scientific article published on 20 October 2010

Ipilimumab for patients with advanced mucosal melanoma

scientific article

Ipilimumab in patients with cancer and the management of dermatologic adverse events

scientific article published on 24 April 2014

Ipilimumab in patients with melanoma and autoimmune disease

scientific article published on 14 October 2014

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

scientific article published on March 27, 2012

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

scientific article

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

scientific article (publication date: 30 June 2011)

Irreversible electroporation facilitates gene transfer of a GM-CSF plasmid with a local and systemic response

scientific article published on September 2013

Is tumor immunity the same thing as autoimmunity? Implications for cancer immunotherapy

article

KIT as a therapeutic target in metastatic melanoma

scientific article published on June 2011

Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation.

scientific article

Keratoacanthomas associated with imatinib mesylate

scientific article published on November 26, 2010

Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells.

scientific article published on 28 September 2016

Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial

scientific article published on 21 September 2017

Localized oncolytic virotherapy inflames distant tumors and synergizes with immune checkpoint blockade leading to systemic tumor rejection

scientific article published on 7 November 2013

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy

scientific article

Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade

scientific article published on 13 February 2020

Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma

scientific article published on 23 December 2020

Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial

scientific article published on 01 April 2003

Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus.

scientific article published on 19 June 2018

MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma

scientific article published on 01 July 2018

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

scientific article published on 14 February 2018

Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma

Matched T cell repertoire analysis of peripheral blood and tumor-infiltrating lymphocytes (TILs) in early stage breast cancer (ESBC) patients (pts) treated with pre-operative cryoablation (cryo) and/or Ipilimumab (Ipi).

scientific article

Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma.

scientific article

Mechanisms of immunization against cancer using chimeric antigens

scientific article

Meeting report: fourth international congress of the Society for Melanoma Research.

scientific article published in February 2008

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

scientific article

Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment

scientific article published on 17 October 2017

Melanoma vaccines

scientific article published on 01 January 2002

Metastasis and immune evasion from extracellular cGAMP hydrolysis

scientific article published on 28 December 2020

Modulation of CTLA-4 and GITR for cancer immunotherapy

scientific article published on January 2011

Modulation of GITR for cancer immunotherapy

scientific article published on January 12, 2012

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand (PD-L)-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

scientific article published on 16 January 2018

Monoclonal antibodies in cancer therapy

scientific article published on 01 May 2012

Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment

scientific article published on 15 December 2011

Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology-molecular associations: clinical and biological implications

scientific article published on 16 December 2016

Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma.

scientific article published on 13 June 2011

Multiple pathways to tumor immunity and concomitant autoimmunity

scientific article

Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma

scientific article published on 17 May 2018

Myeloid-derived suppressor sells and the efficacy of CD8(+) T-cell immunotherapy

scientific article published on February 2013

Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience

scientific article published on 25 March 2019

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

scientific article published on 16 April 2018

Neoantigen quality predicts immunoediting in survivors of pancreatic cancer

scientific article published in June 2022

Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma

scientific article published on 11 April 2022

Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment.

scientific article published on 24 March 2017

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study

scientific article published on 17 October 2017

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

scientific article (publication date: 21 May 2015)

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials

scientific article

Nivolumab plus ipilimumab in advanced melanoma

scientific article

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

scientific article published on 22 October 2018

Non-conventional Inhibitory CD4Foxp3PD-1 T Cells as a Biomarker of Immune Checkpoint Blockade Activity

scientific article published on 01 June 2018

Non-conventional Inhibitory CD4Foxp3PD-1 T Cells as a Biomarker of Immune Checkpoint Blockade Activity

scientific article published on 01 October 2018

Novel cancer immunotherapy agents with survival benefit: recent successes and next steps

scientific article

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis.

scientific article published on 04 May 2009

On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation

scientific article published on March 2015

Opportunistic infections in patients treated with immunotherapy for cancer

scientific article published on 18 June 2014

Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade

scientific article published on 01 August 2019

Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses

scientific article published on January 2009

Optimization of a self antigen for presentation of multiple epitopes in cancer immunity

scientific article

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

scientific article published on 11 September 2017

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.

scientific article published on 9 November 2016

PD-1 Blockers

scientific article published on 01 August 2015

PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance

scientific article published on 29 July 2019

PD-L1 Blockade Therapy: Location, Location, Location

scientific article published on 01 November 2020

PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy

PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.

scientific article published on 5 March 2018

Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor

scientific article published on January 2014

Patient perspectives on ipilimumab across the melanoma treatment trajectory

scientific article

Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses?

scientific article published on December 2012

Patient-Physician Communication in the 21st Century.

scientific article

Patterns of long-term survival following Ipilimumab (Ipi): the Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience

Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC).

scientific article published on 6 November 2014

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

scientific article

Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo.

scientific article published on 25 February 2011

Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients

scientific article published on 3 February 2017

Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma

scientific article published on 16 June 2015

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab.

scientific article published on 6 May 2014

Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab.

scientific article published on 7 November 2013

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma.

scientific article

Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors

scientific article

Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope

scientific article

Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma

scientific article published on April 1, 2003

Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma.

scientific article published on 16 September 2008

Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma

scientific article published on August 5, 2012

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

scientific article published on 18 February 2015

Phase II study of extended-dose temozolomide in patients with melanoma

scientific article published in May 2008

Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma

scientific article published in June 2006

Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma

scientific article published in September 2003

Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.

scientific article published on December 2008

Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.

scientific article published on 26 February 2013

Pilot study of safety and feasibility of DNA microseeding for treatment of spontaneous canine melanoma.

scientific article published on 22 May 2017

Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

scientific article published on 19 September 2016

Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.

scientific article published on 15 September 2017

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

scientific article

Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation of myeloid cells in a preclinical model of prostate cancer

scientific article published on 28 March 2019

Potentiation of immunomodulatory antibodies with oncolytic viruses for therapy of poorly-immunogenic tumors

Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer

scientific article published on 10 December 2014

Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy

scientific article published on 31 January 2018

Pre-operative immunotherapy with tumor cryoablation (cryo) plus ipilimumab (ipi) induces potentially favorable systemic and intratumoral immune effects in early stage breast cancer (ESBC) patients

scientific article

Pre-treatment serum vascular endothelial growth factor is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

scientific article

Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab

scientific article published on February 2014

Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis

scientific article published on 10 June 2016

Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy

scientific article published on 28 November 2018

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma

scientific article published on 31 October 2016

Progression of RAS-mutant leukemia during RAF inhibitor treatment

scientific article published on 7 November 2012

Progressive choroidal thinning (leptochoroid) and fundus depigmentation associated with checkpoint inhibitors

scientific article published on 26 June 2020

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

scientific article

Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab

scientific article published on 8 July 2016

Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer

scientific article published on 01 April 2019

Putting the Immunologic Brakes on Cancer

scientific article published on 01 November 2018

RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group

scientific article published on 26 May 2016

RECIST 1.1-Update and clarification: From the RECIST committee.

scientific article published on 14 May 2016

Radiotherapy after surgical resection for head and neck mucosal melanoma.

scientific article published in June 2010

Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma

scientific article published on May 2013

Rapid enlargement of a malignant melanoma in a child with vitiligo vulgaris after application of topical tacrolimus

scientific article published in April 2008

Rapid eradication of a bulky melanoma mass with one dose of immunotherapy

scientific article published on 20 April 2015

Rational design of anti-GITR-based combination immunotherapy

scientific article published on 29 April 2019

Reassessing the usual suspects causing a commotion in the blood (and vessels?).

scientific article published on 9 January 2004

Recombinant Human Interleukin-7 (CYT107) Enhances CD4 and CD8 T Cell Recovery Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant In Patients with Myeloid Malignancies

scholarly article

Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation

scientific article published on September 25, 2012

Recruit or Reboot? How Does Anti-PD-1 Therapy Change Tumor-Infiltrating Lymphocytes?

scientific article published on 01 September 2019

Refusing to TAP out: 16 new human TEIPPs identified

scientific article published on 21 August 2018

Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas

scientific article published on November 13, 2012

Reply to A. Indini et al

scientific article published on 19 January 2016

Reply to M. Nishino

scientific article published on 25 July 2016

Requirement for innate immunity and CD90⁺ NK1.1⁻ lymphocytes to treat established melanoma with chemo-immunotherapy.

scientific article

Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade.

scientific article published on 16 January 2018

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

scientific article published on 14 November 2016

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

scientific article (publication date: 11 July 2013)

Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor

article by Deborah A. Grosenbaugh et al published December 2011 in American Journal of Veterinary Research

Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma

scientific article

Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma

scientific article published on 28 August 2007

Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors

scientific article published on 01 January 2020

Safety of Infusing Ipilimumab Over 30 Minutes

scientific article published on 29 June 2015

Selecting antigens for cancer vaccines

scientific article published on 10 April 2012

Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications

scientific article

Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids

scientific article published on 19 September 2019

Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response.

scientific article published on 30 March 2009

Shared cancer neoantigens: Making private matters public.

scientific article published on 21 December 2017

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

scientific article

Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade

scientific article published on 12 December 2016

Stage-IV melanoma and pulmonary metastases: factors predictive of survival

scientific article published on 07 August 2007

Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment.

scientific article published on 05 March 2015

Strategies for Predicting Response to Checkpoint Inhibitors

scientific article published on 01 October 2018

Strategies to overcome immune ignorance and tolerance.

scientific article

Successful Treatment of a Patient with Glioblastoma and a Germline POLE Mutation: Where Next?

scientific article

Surgical management of melanoma of the gallbladder: a report of 13 cases and review of the literature

scientific article published on April 2007

Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade

scientific article published on 17 December 2019

T cell receptor diversity evaluation to predict patient response to Ipilimumab in metastatic melanoma

T cells translate individual, quantal activation into collective, analog cytokine responses via time-integrated feedbacks

scientific article published on 09 April 2014

T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression

scientific article

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.

scientific article published on 10 April 2017

Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma

scientific article published on 01 January 2021

Targeting T Cell Co-receptors for Cancer Therapy

scientific article published on May 2016

Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers

scientific article published on May 2010

Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma

Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors

scientific article published on 13 February 2016

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy

scientific article published on 15 April 2014

Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study

scientific article published in June 2005

The Antitumor Immunity of Ipilimumab: (T-cell) Memories to Last a Lifetime?

scientific article published on February 15, 2012

The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy.

scientific article published on 09 June 2015

The PTEN pathway in Tregs functions as a critical driver of the immunosuppressive tumor microenvironment and tolerance to apoptotic cells.

scientific article published on 4 November 2015

The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment

scientific article published on 6 November 2015

The abscopal effect associated with a systemic anti-melanoma immune response

scientific article

The delicate balance of melanoma immunotherapy

scientific article

The efficacy of anti-PD-1 agents in acral and mucosal melanoma

scientific article published on 17 August 2016

The future of cancer immunotherapy: microenvironment-targeting combinations

scientific article published on 28 May 2020

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

scientific article published on 15 March 2016

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

scientific article published on 26 April 2016

The hallmarks of successful anticancer immunotherapy

scientific article published on 01 September 2018

The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases

scientific article

The importance of animal models in tumor immunity and immunotherapy

scientific article

The many faces of the anti-COVID immune response

scientific article published on 01 June 2020

The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation

scientific article published on January 2008

The metabolic/pH sensor soluble adenylyl cyclase is a tumor suppressor protein

scientific article published on 15 June 2016

The role of lipopolysaccharide in T-cell responses following DNA vaccination

scientific article published on 01 March 2003

The role of the immune system in early epithelial carcinogenesis: B-ware the double-edged sword

scientific article published on 01 May 2005

Therapeutic implications of the emerging molecular biology of uveal melanoma.

scientific article

Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab

scientific article published on 31 December 2016

Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy.

scientific article published on 25 April 2016

Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody.

scientific article published on 4 April 2018

Treatment of locally recurrent mucosal melanoma with topical imiquimod

scientific article published on 17 October 2011

Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma

scientific article published on 09 September 2019

Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines

scientific article

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

scientific article published on 14 January 2019

Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner

scientific article published on 22 September 2015

Two Distinct Categories of Focal Deletions in Cancer Genomes

scientific article

Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo

scientific article

Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma

scientific article

Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.

scientific article

Validation of Anti-Mouse PDL-1 Goat Polyclonal Antibody Staining with Mouse PDL-1 In Situ Hybridization on Adjacent Sections of Cell Pellets and Mouse Tumors.

scientific article published in January 2017

WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer.

scientific article published on 08 June 2010

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

scientific article published on 2 March 2017